36.65
-0.69(-1.85%)
Currency In USD
| Previous Close | 37.34 |
| Open | 37.16 |
| Day High | 37.2 |
| Day Low | 36.25 |
| 52-Week High | 98 |
| 52-Week Low | 30.01 |
| Volume | 50,480 |
| Average Volume | 127,944 |
| Market Cap | 343.35M |
| PE | -3.89 |
| EPS | -9.42 |
| Moving Average 50 Days | 48.28 |
| Moving Average 200 Days | 49.06 |
| Change | -0.69 |
If you invested $1000 in Korro Bio, Inc. (KRRO) since IPO date, it would be worth $53.5 as of January 16, 2025 at a share price of $36.65. Whereas If you bought $1000 worth of Korro Bio, Inc. (KRRO) shares 5 years ago, it would be worth $29.13 as of January 16, 2025 at a share price of $36.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
KRRO-110 is the first product candidate from Korro’s proprietary RNA editing OPERATM platformInterim readout from REWRITE expected in the second half of 2025 Korro to advance additional pipeline programs towards clinical development CAMBRIDGE, Mass.,
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent dis
Korro to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 21, 2024 9:01 PM GMT
CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent dis